Stockscreener 앱 받기
0.91%
시간 외 거래:
전일 마감가:
$379.42
열려 있는:
$380.02
하루 거래량:
2.45M
Relative Volume:
0.86
시가총액:
$206.39B
수익:
$36.74B
순이익/손실:
$7.71B
주가수익비율:
26.90
EPS:
14.2333
순현금흐름:
$8.10B
1주 성능:
+2.55%
1개월 성능:
+11.06%
6개월 성능:
+30.35%
1년 성능:
+23.62%
1일 변동 폭
$378.82
$383.20
1주일 범위
$370.44
$383.20
52주 변동 폭
$261.43
$385.12
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
382.87 | 204.53B | 36.74B | 7.71B | 8.10B | 14.23 |
|
LLY
Lilly Eli Co
|
1,042.15 | 998.60B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
246.28 | 592.45B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
228.44 | 405.58B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
206.61 | 317.72B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
167.11 | 314.27B | 54.72B | 14.02B | 15.32B | 7.1855 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-01-20 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-05 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-11-24 | 재개 | Truist | Hold |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-03 | 재개 | Raymond James | Mkt Perform |
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE - PR Newswire
Amgen Inc. $AMGN Shares Sold by M. Kulyk & Associates LLC - MarketBeat
Dakota Wealth Management Has $9.15 Million Holdings in Amgen Inc. $AMGN - MarketBeat
EverSource Wealth Advisors LLC Has $5.40 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen’s New UPLIZNA Nod and $4 Billion Bond Sale Might Change The Case For Investing In Amgen (AMGN) - simplywall.st
Amgen Inc. (AMGN): Investor Outlook On A Healthcare Giant With A 2.58% Dividend Yield - DirectorsTalk Interviews
Barclays begins Amgen (AMGN) coverage, notes balanced outlook despite trial debate - MSN
FY2026 EPS Estimates for Amgen Increased by Erste Group Bank - MarketBeat
Is Amgen (AMGN) Still Attractively Priced After Strong Multi Year Share Price Gains - simplywall.st
Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate - Insider Monkey
Lansforsakringar Fondforvaltning AB publ Has $53.27 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Upgraded at Barclays - Defense World
Smead Capital Management Inc. Cuts Position in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Rating Increased to Hold at Barclays - MarketBeat
Amgen (NASDAQ:AMGN) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Amgen VP Busch sells $375k in AMGN stock - Investing.com
Amgen VP Busch sells $375k in AMGN stock By Investing.com - Investing.com South Africa
The Analyst Verdict: Amgen In The Eyes Of 18 Experts - Benzinga
Here are Friday’s top Wall Street analyst research calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and more - MSN
Barclays Begins Coverage on Amgen (NASDAQ:AMGN) - MarketBeat
Barclays Initiates Coverage on Amgen (AMGN) with Equal-Weight Ra - GuruFocus
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Bitget
Barclays Initiates Coverage of Amgen (AMGN) with Equal-Weight Recommendation - Nasdaq
ICICI Prudential Asset Management Co Ltd Purchases 8,529 Shares of Amgen Inc. $AMGN - MarketBeat
Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More - 24/7 Wall St.
Barclays initiates Amgen stock coverage with Equalweight rating - Investing.com
Sandoz Mulls Appeal As US Court Dismisses Amgen Enbrel Antitrust Complaint - Citeline News & Insights
Amgen Inc. $AMGN Shares Acquired by China Universal Asset Management Co. Ltd. - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN) Announces Successful Issuance of $4 Billion in Senior Notes - GuruFocus
Amgen Prices $4 Billion Senior Unsecured Notes Offering - TipRanks
Amgen raises $4bn across four tranches as Amazon lurks - GlobalCapital
Amgen (NASDAQ: AMGN) sells four new series of senior notes - Stock Titan
Here's What the Street is Saying About Amgen Inc. (AMGN) - Finviz
Here’s what the street is saying about Amgen Inc. (AMGN) - MSN
Here’s What the Street is Saying About Amgen Inc. (AMGN) - Insider Monkey
P/E Ratio Insights for Amgen - Benzinga
Amgen (AMGN) Gets Target Price Increase by Wells Fargo | AMGN St - GuruFocus
Pharma Giants Amgen & Abbott Labs Commit to Transition Away from Horseshoe Crab Blood in Biomedical Testing Following Shareholder Engagement - As You Sow
NewEdge Wealth LLC Raises Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Axxcess Wealth Management LLC Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
Hodges Capital Management Inc. Sells 6,887 Shares of Amgen Inc. $AMGN - MarketBeat
Sandoz's Case Against Amgen Over Enbrel Biosimilar Tossed - Law360
Here’s what Argus Research and Guggenheim are saying about Amgen Inc. (AMGN) - MSN
Amgen Details Oncology R&D Push, IMDELLTRA Expansion and LUMAKRAS Updates at Citi Summit - MarketBeat
Amgen at Citi’s 2026 Virtual Oncology Summit: Expanding Cancer Therapies - Investing.com
AMGN: Transformative oncology pipeline advances with T cell engagers, AI, and precision therapies - TradingView
Wells Fargo Adjusts Amgen Price Target to $375 From $325, Maintains Equal Weight Rating - marketscreener.com
Rothschild & Co Redburn Boosts Amgen (NASDAQ:AMGN) Price Target to $200.00 - MarketBeat
Piper Sandler raises Amgen stock price target on drug pipeline - Investing.com
Amgen Stock Is Up 14% This Year on Dual Drug Approvals. Can the Rally Hold? - TIKR.com
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.46%
0.30%
자본화:
|
볼륨(24시간):